Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $24.50 Average PT from Analysts

by · The Markets Daily

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) have earned a consensus recommendation of “Hold” from the eleven analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $24.50.

ATXS has been the topic of several research analyst reports. JMP Securities reaffirmed a “market perform” rating on shares of Astria Therapeutics in a research report on Wednesday, October 15th. Citizens Jmp lowered shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 15th. Evercore ISI reaffirmed an “outperform” rating and issued a $26.00 price target on shares of Astria Therapeutics in a research note on Wednesday, October 1st. HC Wainwright lowered shares of Astria Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 16th. Finally, Cantor Fitzgerald cut shares of Astria Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Wednesday, November 12th.

Check Out Our Latest Stock Report on ATXS

Astria Therapeutics Trading Up 0.8%

ATXS stock opened at $13.09 on Monday. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $13.29. The stock has a market cap of $747.18 million, a PE ratio of -6.12 and a beta of 0.07. The company has a 50-day moving average price of $12.69 and a 200 day moving average price of $9.08.

Astria Therapeutics (NASDAQ:ATXS – Get Free Report) last announced its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.14). The business had revenue of $0.71 million during the quarter, compared to analyst estimates of $10.67 million. Sell-side analysts forecast that Astria Therapeutics will post -1.65 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its holdings in shares of Astria Therapeutics by 185.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,557 shares during the period. Cubist Systematic Strategies LLC increased its stake in shares of Astria Therapeutics by 503.7% during the first quarter. Cubist Systematic Strategies LLC now owns 92,239 shares of the biotechnology company’s stock valued at $493,000 after buying an additional 76,961 shares during the period. Hsbc Holdings PLC raised its holdings in shares of Astria Therapeutics by 70.3% in the first quarter. Hsbc Holdings PLC now owns 32,808 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 13,545 shares in the last quarter. Affinity Asset Advisors LLC purchased a new stake in Astria Therapeutics in the second quarter worth about $1,608,000. Finally, Panagora Asset Management Inc. purchased a new stake in Astria Therapeutics in the second quarter worth about $528,000. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

(Get Free Report)

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.

Featured Articles